Literature DB >> 341947

Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens.

S Montgomery, R McAuley, D B Montgomery.   

Abstract

1. Twenty-six in-patients and 24 out-patients suffering from moderate or severe primary depressive illness were randomly allocated to either a single night-time dose of mianserin 60 mg or a three times daily regimen in a double-blind controlled trial. 2. There was no significant difference in antidepressant effect between the two dosage regimens in either patient group measured using Hamilton Rating Scale (HRS), the Beck Self-Rating Inventory (BSRI) and the new Montgomery and Asberg Depression Scale (MADS). 3. A significant negative correlation (-0.36 P less than 0.05) was found between plasma levels and clinical response using the MADS. A trend for patients with low levels to do worse was also observed suggesting a curvilinear relationship. A highly significant poorer clinical response in patients with levels above 70 microgram/1 was observed using the MADS (t = 3.33, P less than 0.005). This was also seen with the HRS (t = 2.42, P less than 0.02). 4. A significant correlation (r = 0.29, P less than 0.05) with age is reported, and a highly significant increased variability (F = 7.07, P less than 0.001) of mianserin plasma levels in patients over 55 was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 341947      PMCID: PMC1429212     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

2.  Routine nortriptyline levels in treatment of depression.

Authors:  S A Montgomery; R A Braithwaite; J L Crammer
Journal:  Br Med J       Date:  1977-07-16

3.  Plasma-nortriptyline levels in endogenous depression.

Authors:  P Kragh-Sørensen; M Asberg; C Eggert-Hansen
Journal:  Lancet       Date:  1973-01-20       Impact factor: 79.321

4.  Plasma concentration of nortriptyline and clinical response in depressive illness.

Authors:  G D Burrows; B Davies; B A Scoggins
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

5.  Studies in the classification of affective disorders. The relationship between anxiety states and depressive illnesses. II.

Authors:  C Gurney; M Roth; R F Garside; T A Kerr; K Schapira
Journal:  Br J Psychiatry       Date:  1972-08       Impact factor: 9.319

6.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

7.  Diagnostic criteria for use in psychiatric research.

Authors:  J P Feighner; E Robins; S B Guze; R A Woodruff; G Winokur; R Munoz
Journal:  Arch Gen Psychiatry       Date:  1972-01

8.  A comparison study of amitriptyline and nortriptyline with plasma levels.

Authors:  V E Ziegler; P J Clayton; J T Biggs
Journal:  Arch Gen Psychiatry       Date:  1977-05

9.  Mianserin hydrochloride: a novel antidepressant.

Authors:  A Coppen; R Gupta; S Montgomery; K Ghose; J Bailey; B Burns; J J de Ridder
Journal:  Br J Psychiatry       Date:  1976-10       Impact factor: 9.319

10.  Nortriptyline plasma levels and therapeutic response.

Authors:  V E Ziegler; P J Clayton; J R Taylor; B Tee; J T Biggs
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

View more
  13 in total

1.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.

Authors:  Gisa Gerstenberg; Toshiaki Aoshima; Takashi Fukasawa; Keizo Yoshida; Hitoshi Takahashi; Hisashi Higuchi; Yoshiko Murata; Ritsuko Shimoyama; Tadashi Ohkubo; Tetsuo Shimizu; Koichi Otani
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

2.  Variability in the elimination of mianserin in elderly patients.

Authors:  E J Begg; J R Sharman; J E Kidd; R Sainsbury; D W Clark
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

3.  Plasma concentrations of mianserin after single dose and at steady-state in depressed elderly patients.

Authors:  S Dawling; S Ford; P Ariyanayagam; H O'Neal; R R Lewis
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

4.  Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline.

Authors:  S Montgomery; B Cronholm; M Asberg; D B Montgomery
Journal:  Br J Clin Pharmacol       Date:  1978       Impact factor: 4.335

Review 5.  Antidepressant overdosage.

Authors:  P Crome
Journal:  Drugs       Date:  1982-06       Impact factor: 9.546

Review 6.  Measurement of serum drug levels in the assessment of antidepressants.

Authors:  S A Montgomery
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

Review 7.  Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-10       Impact factor: 9.546

8.  Absence of an effect of mianserin on the actions of clonidine or methyldopa in hypertensive patients.

Authors:  H L Elliott; K McLean; D J Sumner; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Mianserin and doxepin in the treatment of outpatient depression with anxiety.

Authors:  M C Khan; E H Bennie; S M Stulemeijer; M A Ravens
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

10.  Mianserin: cardiovascular effects in elderly patients.

Authors:  M Møller; P Thayssen; P Kragh-Sørensen; O L Pedersen; C B Kristensen; M Bjerre; S Benjaminsen; L F Gram
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.